X-ray crystal structure of lovastatin bound to the CD11a I-domain of beta 2 integrin, LFA-1. PDB ID: 1CQP, Kallen et al., J. Mol. Biol. 1999, 292, 1–9

Integrin Targeted Drug Discovery


Thursday, 28th March 2019


Royal Society of Chemistry at Burlington House, London, UK



Registration is not yet open


Downloads and Links
First announcement and call for abstracts

Abstract template - closing dates are 14th September (oral) and 31st December (poster)

Directions to the venue
RSC website


Integrins are heterodimeric, transmembrane receptors that function in cell adhesion and signalling. They are central to many disease states, including cancer, thrombosis, multiple sclerosis and Crohn’s disease. Integrin targeted therapeutics have been under investigation for some time, but few compounds have made it to/ remained on the market due to side effects or lack of efficacy. Given the more recent structural insights, better understanding of downstream pathways, and potential application to a range of therapeutic areas, there has been a resurgence of interest in integrin inhibitors. This symposium will bring together researchers in this area to provide both a historical overview of the area and recent progress in designing the next generation of integrin inhibitors.


Who should attend
Scientists from industry and academia, including medicinal and computational chemists.


Features of the Meeting
Therapeutic targets for integrins
Targeting different RGD recognising integrins
Drug discovery, medicinal chemistry and structure-based design
Plenary speakers, poster session and trade exhibition

Call for Abstracts
Applications for oral and poster presentations are welcomed. Posters will be displayed throughout the day, and applicants will be asked if they would like to provide a two-minute flash oral presentation when submitting their abstract. Closing dates are 14th September 2018 for oral and 31st December 2018 for poster submissions.


Please download an abstract template here.


Confirmed Speakers

Prof Dermot Cox, Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland
Prof Daria Giacomini, Chemistry, University of Bologna
Dr Simon Goodman, formerly of Preclinical Oncology, Merck Serono
Prof Dr Horst Kessler, Chemistry, Technical University of Munich
Dr Helen Sheldrake, Cancer Therapeutics, University of Bradford


Registration will open in Spring 2018, and discounted rates will be available for students and RSC members. In addition, a number of student bursaries will be available for post-graduate students.


A relevant trade exhibition will add value to the symposium.   The exhibition will be held in the same room as the catering (refreshments and lunch) and posters, and the exhibition package will include:
- chair and table
- electrical access and wi-fi access

- one full delegate attendance.

Those companies wishing to have a trade stand should register an interest with the secretariat.  There will be an opportunity to book delegate pack inserts.


Venue and Travel
The symposium will be held in the Science and Fish Rooms, Royal Society of Chemistry at Burlington House, Piccadilly, London, W1J 0BA, UK. Directions to venue.

Situated in central London, the RSC is easily accessible by public transport, and close to Green Park tube station.


Sponsors are encouraged to support this event, which will help us to offer inexpensive registration fees to young chemists.


Organising Committee
Richard Hatley, GlaxoSmithKline
Douglas Williamson, Vernalis (chairman)
Alison Woolford, Astex Therapeutics

Secretariat Contact
Maggi Churchouse, 3 East Barn, Market Weston Road, Thelnetham, Diss IP22 1JJ, UK
Telephone: +44 (0)1359 221004
E-mail:  maggi@maggichurchouseevents.co.uk


To register an interest and to be notified when registration is open, please e-mail the Secretariat.


Registration is not yet open



Please click to view other BMCS events